Background: α-tocopherol (AT) and γ-tocotrienol (GT3) are vitamin E isoforms considered to have potential chemopreventive properties. AT has been widely studied in vitro and in clinical trials with mixed results. The latest clinical study (SELECT trial) tested AT in prostate cancer patients, determined that AT provided no benefit, and could promote cancer. Conversely, GT3 has shown antineoplastic properties in several in vitro studies, with no clinical studies published to date. GT3 causes apoptosis via upregulation of the JNK pathway; however, inhibition results in a partial block of cell death. We compared side by side the mechanistic differences in these cells in response to AT and GT3.
Methods: The effects of GT3 and AT were studied on androgen sensitive LNCaP and androgen independent PC-3 prostate cancer cells. Their cytotoxic effects were analyzed via MTT and confirmed by metabolic assays measuring ATP. Cellular pathways were studied by immunoblot. Quantitative analysis and the determination of relationships between cell signaling events were analyzed for both agents tested. Non-cancerous prostate RWPE-1 cells were also included as a control.
Results: The RAF/RAS/ERK pathway was significantly activated by GT3 in LNCaP and PC-3 cells but not by AT. This activation is essential for the apoptotic affect by GT3 as demonstrated the complete inhibition of apoptosis by MEK1 inhibitor U0126. Phospho-c-JUN was upregulated by GT3 but not AT. No changes were observed on AKT for either agent, and no release of cytochrome c into the cytoplasm was detected. Caspases 9 and 3 were efficiently activated by GT3 on both cell lines irrespective of androgen sensitivity, but not in cells dosed with AT. Cell viability of non-cancerous RWPE-1 cells was affected neither by GT3 nor AT.
Conclusions: c-JUN is a recognized master regulator of apoptosis as shown previously in prostate cancer. However, the mechanism of action of GT3 in these cells also include a significant activation of ERK which is essential for the apoptotic effect of GT3. The activation of both, ERK and c-JUN, is required for apoptosis and may suggest a relevant step in ensuring circumvention of mechanisms of resistance related to the constitutive activation of MEK1.
Keywords: Differential effect; Prevention; Prostate cancer; Vitamin E isoforms; α-Tocopherol; γ-Tocotrienol.
Conflict of interest statement
The authors declare that they have no competing interests.
γ-Tocotrienol induces apoptosis in pancreatic cancer cells by upregulation of ceramide synthesis and modulation of sphingolipid transport.BMC Cancer. 2018 May 16;18(1):564. doi: 10.1186/s12885-018-4462-y. BMC Cancer. 2018. PMID: 29769046 Free PMC article.
γ-Tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer.Free Radic Biol Med. 2011 May 15;50(10):1344-54. doi: 10.1016/j.freeradbiomed.2011.02.007. Epub 2011 Feb 16. Free Radic Biol Med. 2011. PMID: 21335085
C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.Oncogene. 2002 Feb 7;21(7):1017-27. doi: 10.1038/sj.onc.1205167. Oncogene. 2002. PMID: 11850819
Vitamin E and its anticancer effects.Crit Rev Food Sci Nutr. 2019;59(17):2831-2838. doi: 10.1080/10408398.2018.1474169. Epub 2018 Oct 23. Crit Rev Food Sci Nutr. 2019. PMID: 29746786 Review.
Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy.Anticancer Agents Med Chem. 2013 Sep;13(7):1039-47. doi: 10.2174/18715206113139990116. Anticancer Agents Med Chem. 2013. PMID: 23272909 Review.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
- Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology. 1997;50(6):840–848. - PubMed
- Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004;54(3):150–180. - PubMed
- Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res. 1993;34(3):343–358. - PubMed